Ayse Armutlu

Ayse Armutlu

Auto-generated profile, based on publicly available information

Ayse Armutlu

Department of Pathology, Koc University School of Medicine, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in European Journal of Radiology
Verified
Journal Article
Closed access
AOAslıhan Onay
Aslıhan Onay
MVMetin Vural
Metin Vural
AAAyse Armutlu
Ayse Armutlu
SYSevda Ozel Yıldız
Sevda Ozel Yıldız
MKMurat Can Kiremit
Murat Can Kiremit
BBBarıs Bakır
Barıs Bakır

11 May 2021 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAydanur Senturk
Aydanur Senturk
ASAyse T. Sahin
Ayse T. Sahin
AAAyse Armutlu
Ayse Armutlu
MKMurat C. Kiremit
Murat C. Kiremit
OAOmer Acar
Omer Acar
NONurhan Ozlu
Nurhan Ozlu
Clear cell renal cell carcinoma (ccRCC) is the third most common and most malignant urological cancer, with a 5-year survival rate of 10% for patients with advanced tumors. Here, we identified 10,160 unique proteins by in-depth quantitative proteomics, of which 955 proteins were significantly regulated between tumor and normal adjacent tissues. We verified four putatively secreted biomarker candidates, namely, PLOD2, FERMT3, SPARC, and SIRPα, as highly expressed proteins that are not affected by intratumor and intertumor heterogeneity. Moreover, SPARC displayed a significant increase in urine samples of patients with ccRCC, making it a promising marker for the detection of the disease in body fluids. Furthermore, based on molecular expression profiles, we propose a biomarker panel for the robust classification of ccRCC tumors into two main clusters, which significantly differed in patient outcome with an almost three times higher risk of death for cluster 1 tumors compared with cluster 2 tumors. Moreover, among the most significant clustering proteins, 13 were targets of repurposed inhibitory FDA-approved drugs. Our rigorous proteomics approach identified promising diagnostic and tumor-discriminative biomarker candidates which can serve as therapeutic targets for the treatment of ccRCC. Implications: Our in-depth quantitative proteomics analysis of ccRCC tissues identifies the putatively secreted protein SPARC as a promising urine biomarker and reveals two molecular tumor phenotypes.


21 September 2022 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
ASAydanur Senturk
Aydanur Senturk
ASAyse T. Sahin
Ayse T. Sahin
AAAyse Armutlu
Ayse Armutlu
MKMurat Can Kiremit
Murat Can Kiremit
OAOmer Acar
Omer Acar
NONurhan Ozlu
Nurhan Ozlu
Clear cell Renal Cell Carcinoma (ccRCC) is among the 10 most common cancers in both men and women and causes more than 140,000 deaths worldwide every year. In order to elucidate the underlying molecular mechanisms orchestrated by phosphorylation modifications, we performed a comprehensive quantitative phosphoproteomics characterization of ccRCC tumor and normal adjacent tissues. Here, we identified 16,253 phosphopeptides, of which more than 9000 were singly quantified. Our in-depth analysis revealed 600 phosphopeptides to be significantly differentially regulated between tumor and normal tissues. Moreover, our data revealed that significantly up-regulated phosphoproteins are associated with protein synthesis and cytoskeletal re-organization which suggests proliferative and migratory behavior of renal tumors. This is supported by a mesenchymal profile of ccRCC phosphorylation events. Our rigorous characterization of the renal phosphoproteome also suggests that both epidermal growth factor receptor and vascular endothelial growth factor receptor are important mediators of phospho signaling in RCC pathogenesis. Furthermore, we determined the kinases p21-activated kinase 2, cyclin-dependent kinase 1 and c-Jun N-terminal kinase 1 to be master kinases that are responsible for phosphorylation of many substrates associated with cell proliferation, inflammation and migration. Moreover, high expression of p21-activated kinase 2 is associated with worse survival outcome of ccRCC patients. These master kinases are targetable by inhibitory drugs such as fostamatinib, minocycline, tamoxifen and bosutinib which can serve as novel therapeutic agents for ccRCC treatment.

28 September 2018 in Turkish Archives of Otorhinolaryngology
Verified
Journal Article
Closed access
OGOzan Gokler
Ozan Gokler
IKIsil Karanfil
Isil Karanfil
IKIlker Kocak
Ilker Kocak
MAMuzaffer Ozan Altuntas
Muzaffer Ozan Altuntas
AAAyse Armutlu
Ayse Armutlu
OUOmer Faruk Unal
Omer Faruk Unal
Türk Otorinolarengoloji Arşivi

14 June 2021 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDF file
AAAyşe Armutlu
Ayşe Armutlu
OSOmer Saeed
Omer Saeed
RSRomil Saxena
Romil Saxena
We analyzed metastatic liver tumors received in the department of pathology in a tertiary care center over a 3-year period. There were 509 metastatic liver tumors; counterintuitively, there were as many resections (235 cases) as biopsies (274 cases). This unexpected finding reflects contemporaneous organ-specific paradigms for diagnosis and management of metastatic liver disease in oncologic practice, and the association of our practice with a National Cancer Institute-designated comprehensive cancer center with expertise and specialization in liver surgery. We receive a large number of resections for metastatic liver tumors because metastasectomy from a variety of primary tumors is associated with improved overall, and in many instances, disease-free, long-term survival. Metastatic colorectal carcinomas, metastatic neuroendocrine tumors, and metastatic gastrointestinal stromal tumors constituted 78% of resections because the largest body of literature and cumulative experience exists for these lesions. In contrast, breast carcinomas and pancreatic carcinomas, which are the next common metastatic liver tumors were biopsied but rarely resected, because metastasectomy is not the standard of care for these tumors. Immunohistochemistry was performed in less than a quarter of the total number of cases (23%), because the primary tumor site was known in the vast majority of cases. Of the 42 cases with unknown primary tumor, it was elucidated in 50% of the cases by immunohistochemical and clinical work-up. Of the cases with known primary tumor, immunohistochemistry was performed mostly in metastatic breast, colon, and lung carcinomas. In these cases, biomarker analyses provided additional information relevant to clinical management.